Iron Deficiency and Anemia in Cancer Patients: The Role of Iron Treatment in Anemic Cancer Patients

References

• Ludwig H, Muldur E, Endler G, and Hubl W: Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 24, 1886–1892, 2013.
   PubMed Web of Science ®Google Scholar
• Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, et al.: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361, 2436–2448, 2009.
   PubMed Web of Science ®Google Scholar
• Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL, et al.: Prevalence of iron deficiency in the United States. JAMA 277, 973–976, 1997.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, et al.: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40, 2293–2306, 2004.
   PubMed Web of Science ®Google Scholar
• Grotto HZ: Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol 25, 12–21, 2008.
   PubMed Web of Science ®Google Scholar
• Gilreath JA, Stenehjem DD, and Rodgers GM: Diagnosis and treatment of cancer-related anemia. Am J Hematol 89, 203–212, 2014.
   PubMed Web of Science ®Google Scholar
• Gaspar BL, Sharma P, and Das R: Anemia in malignancies: pathogenetic and diagnostic considerations. Hematology 20, 18–25, 2015.
   PubMed Web of Science ®Google Scholar
• Adamson JW: The anemia of inflammation/malignancy: mechanisms and management. Hematol Am Soc Hematol Educ Program 2008, 159–165, 2008.
   Google Scholar
• Aapro M, Osterborg A, Gascon P, Ludwig H, and Beguin Y: Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 23, 1954–1962, 2012.
   PubMed Web of Science ®Google Scholar
• Weiss G, and Goodnough LT: Anemia of chronic disease. N Engl J Med 352, 1011–1023, 2005.
   PubMed Web of Science ®Google Scholar
• Tilg H, Ulmer H, Kaser A, and Weiss G: Role of IL-10 for induction of anemia during inflammation. J Immunol 169, 2204–2209, 2002.
   PubMed Web of Science ®Google Scholar
• Goodnough LT, Nemeth E, and Ganz T: Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 116, 4754–4761, 2010.
   PubMed Web of Science ®Google Scholar
• Crawford J, Cella D, Cleeland CS, Cremieux P-Y, Demetri GD, et al.: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95, 888–895, 2002.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Muldur E, Endler G, et al.: High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status. Haematologica 96, 409, 2011.
   Google Scholar
• Brownlie T, Utermohlen V, Hinton PS, and Haas JD: Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 79, 437–443, 2004.
   PubMed Web of Science ®Google Scholar
• Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J, et al.: Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet 348, 992–996, 1996.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A, and Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91, 2214–2221, 2001.
   PubMed Web of Science ®Google Scholar
• Schito L, and Semenza GL: Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer 2, 758–770, 2016.
   PubMed Web of Science ®Google Scholar
• Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SN, et al.: Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res 35, 579–584, 2011.
   PubMed Web of Science ®Google Scholar
• Semenza GL: Hif-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8, S62–S67, 2002.
   PubMed Web of Science ®Google Scholar
• Harrison LB, Chadha M, Hill RJ, Hu K, and Shasha D: Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7, 492–508, 2002.
   PubMed Web of Science ®Google Scholar
• Vaupel P, and Harrison L: Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9, 4–9, 2004.
   PubMed Web of Science ®Google Scholar
• Vamvakas EC, and Blajchman MA: Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 113, 3406–3417, 2009.
   PubMed Web of Science ®Google Scholar
• Marik PE, and Corwin HL: Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 36, 2667–2674, 2008.
   PubMed Web of Science ®Google Scholar
• Thomson A, Farmer S, Hofmann A, Isbister J, Shander A, et al.: Patient blood management—a new paradigm for transfusion medicine? ISBT Sci Ser 4, 423–435, 2009.
   PubMedGoogle Scholar
• Rawn J: The silent risks of blood transfusion. Curr Opin Anaesthesiol 21, 664–668, 2008.
   PubMed Web of Science ®Google Scholar
• Amato AC, and Pescatori M: Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors. Dis Colon Rectum 41, 570–585, 1998.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al.: Erythropoietin or darbepoetin for patients with cancer–meta-analysis based on individual patient data. Cochrane Database Syst Rev 3, CD007303, 2009.
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, et al.: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19, 2875–2882, 2001.
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B, et al.: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19, 2865–2874, 2001.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Aapro M, Bokemeyer C, Macdonald K, Soubeyran P, et al.: Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the anaemia cancer treatment (ACT) study. Eur J Cancer 45, 1603–1615, 2009.
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, et al.: American society of hematology/American society of clinical oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116, 4045–4059, 2010.
   PubMed Web of Science ®Google Scholar
• EMA. Summary of Scientific Discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion_-_Variation/human/000332/WC500026146.pdf. Accessed 2015.
   Google Scholar
• FDA. Procrit Label, Epogen Label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s5199lbl.pdf. Accessed 2015.
   Google Scholar
• FDA. Aranesp (Darbepoetin Alfa) for Injection. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103951s5197lbl.pdf. Accessed 2015.
   Google Scholar
• NCCN. Cancer- and Chemotherapy-Induced Anemia, Version 2.2014. http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf (2014). Accessed 2015.
   Google Scholar
• Toblli JE, and Angerosa M: Optimizing iron delivery in themanagement of anemia: patient considerations and the role of ferric carboxy maltose. Drug Des Dev Ther 8, 2475–2491, 2014.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, et al.: Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr 127, 907–919, 2015.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, et al.: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22, 1301–1307, 2004.
   PubMed Web of Science ®Google Scholar
• Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, et al.: Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21, 627–632, 2007.
   PubMed Web of Science ®Google Scholar
• Henry DH: Epoetin alfa treatment for patients with chemotherapy-induced anemia. Support Cancer Ther 4, 78–91, 2007.
   PubMedGoogle Scholar
• Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, et al.: Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26, 1611–1618, 2008.
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, et al.: Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 26, 1619–1625, 2008.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, et al.: Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 85, 655–663, 2010.
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Rozen-Zvi B, Vidal L, Leibovici L, Vansteenkiste J, et al.: Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia—systematic review and meta-analysis of randomised controlled trials. Acta Oncol 52, 18–29, 2013.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, Lonati V, and Barni S: Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol 138, 179–187, 2012.
   PubMed Web of Science ®Google Scholar
• Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, et al.: Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 24, 475–482, 2013.
   PubMed Web of Science ®Google Scholar
• Dangsuwan P, and Manchana T: Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 116, 522–525, 2010.
   PubMed Web of Science ®Google Scholar
• Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, et al.: Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 105, 199–204, 2007.
   PubMed Web of Science ®Google Scholar
• Athibovonsuk P, Manchana T, and Sirisabya N: Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol. Oncol 131, 679–682, 2013.
   PubMed Web of Science ®Google Scholar
• Hedenus M, Karlsson T, Ludwig H, Rzychon B, Felder M, et al.: Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med. Oncol 31, 302, 2014.
   PubMed Web of Science ®Google Scholar
• Verhaeghe L, Bruyneel L, Stragier E, Ferrante M, Dierickx D, and Prenen H: The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: a retrospective study. Ann. Gastroenterol 30, 654–663, 2017.
   PubMed Web of Science ®Google Scholar
• Coussirou J, Debourdeau A, Stancu A, Jean C, Azouza W, et al.: Impact of ferric carboxymaltose on the evolution of hemoglobin and ecog performance status in iron-deficient patients with solid tumors: a 3-month follow-up retrospective study. Support Care Cancer 26, 3827–3834, 2018.
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Abbasi S, Saadi I, Jaber R, Abdelelah H, et al.: Intravenous iron monotherapy for the treatment of non-iron deficiency anemia in cancer patients undergoing chemotherapy: a pilot study. Drug Design. Drug Des Devel Ther 7, 939–944, 2013.
   PubMed Web of Science ®Google Scholar
• Keeler BD, Simpson JA, Ng S, Tselepis C, Iqbal T, et al.: The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer. Colorectal Dis 16, 794–800, 2014.
   PubMed Web of Science ®Google Scholar
• Toledano A, Luporsi E, Morere JF, Scotté F, Laribi K, et al.: Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support Care Cancer 24, 67–75, 2016.
   PubMed Web of Science ®Google Scholar
• Calleja JL, Delgado S, del Val A, Hervás A, Larraona JL, et al.: Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int J Colorectal Dis 31, 543–551, 2016.
   PubMed Web of Science ®Google Scholar
• Yoon HM, Kim YW, Nam BH, Reim D, Eom BW, et al.: Intravenous iron supplementation may be superior to observation in acute isovolemic anemia after gastrectomy for cancer. Word J Gastroenterol 20, 1852–1857, 2014.
   PubMed Web of Science ®Google Scholar
• Titos-Arcos JC, Soria-Aledo V, Carrillo-Alcaraz A, Ventura-López M, Palacios-Muñoz S, et al.: Is intravenous iron useful for reducing transfusions in surgically treated colorectal cancer patients? World J Surg 36, 1893–1897, 2012.
   PubMed Web of Science ®Google Scholar
• Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR, et al.: Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12, 231–242, 2007.
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, et al.: Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 26, 1619–1625, 2008.
   PubMed Web of Science ®Google Scholar
• Jaspers A, Baron F, Maertens J, De Prijck B, Schots R, et al.: Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation. Am J Hematol 90, e133–e134, 2015.
   PubMed Web of Science ®Google Scholar
• Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J, et al.: Body iron metabolism and pathophysiology of iron overload. Int J Hematol 88, 7–15, 2008.
   PubMed Web of Science ®Google Scholar
• Kruszewski M: Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 531, 81–92, 2003.
   PubMed Web of Science ®Google Scholar
• Nelson RL: Iron and colorectal cancer risk: human studies. Nutr Rev 59, 140–148, 2001.
   PubMed Web of Science ®Google Scholar
• Rezazadeh H, Nayebi AR, Garjani A, Sheikhulislami A, Babaei H, et al.: Evidence that iron overload plus croton oil induce skin tumours in mice. Hum Exp Toxicol 24, 409–413, 2005.
   PubMed Web of Science ®Google Scholar
• Bergeron RJ, Streiff RR, and Elliott GT: Influence of iron on in vivo proliferation and lethality of L1210 cells. J Nutr 115, 369–374, 1985.
   PubMed Web of Science ®Google Scholar
• Keating GM: Ferric carboxymaltose: a review of its use in iron deficiency. Drugs 75, 101–127, 2015. doi: 10.1007/s40265-014-0332-3.
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Spellberg B, Walsh TJ, and Kontoyiannis DP: Pathogenesis of mucormycosis. CID 54, S16–S22, 2012.
   PubMed Web of Science ®Google Scholar
• Nairz M, Schroll A, Demetz E, Tancevski I, Theurl I, et al.: 'Ride on the ferrous wheel'-the cycle of iron in macrophages in health and disease. Immunobiology 220, 280–294, 2015.
   PubMed Web of Science ®Google Scholar
• Dadwal SS, Tegtmeier B, Liu X, Frankel P, Ito J, et al.: Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 94, 235–242, 2015.
   PubMed Web of Science ®Google Scholar
• Patil PS, Mohandas KM, Bhatia SJ, and Mehta SA: Serum ferritin and the risk of hepatocellular carcinoma in chronic liver disease of viral etiology: a case-control study. Indian J Gastroenterol 33, 12–18, 2014.
   PubMedGoogle Scholar
• Gilreath JA, Stenehjem DD, and Rodgers GM: Total dose iron dextran infusion in cancer patients: is it safe? J Natl Compr Canc Netw 10, 669–676, 2012.
   PubMed Web of Science ®Google Scholar